Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: A secondary analysis of a randomized clinical trial

Authors

Alexander M M Eggermont, Universite Paris-Saclay
Leonel Hernandez-Aya, Washington University School of Medicine in St. Louis
et al

Journal

JAMA Oncology

Publication Date

4-1-2020

Volume

6

Issue

4

First Page

519

Last Page

527

Document Type

Open Access Publication

DOI

10.1001/jamaoncol.2019.5570

Rights and Permissions

Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Krepler C, Ibrahim N, Marreaud S, van Akkooi A, Robert C, Suciu S. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2020 Apr 1;6(4):519-527. doi: 10.1001/jamaoncol.2019.5570 This is an open access article distributed under the terms of the CC-BY-NC-ND License. © 2020 Eggermont AMM et al. JAMA Oncology.

Recommended Citation

Eggermont, Alexander M M; Hernandez-Aya, Leonel; and et al, "Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: A secondary analysis of a randomized clinical trial." JAMA Oncology. 6, 4. 519 - 527. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/12034